CRISPR Therapeutics details CTX310 reduction data, names new CTO and CFONov 9Regulatory decisionCRISPR Therapeutics AGCTX310Updated
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340